NEW YORK (GenomeWeb News) – Biocept said after the close of the market on Monday that it has closed its initial public offering, raising $19 million in gross proceeds.

The company went public last week with an offering of 1.9 million shares at $10 per share. In afternoon trading on the Nasdaq, Biocept's shares were down a fraction of 1 percent at $8.85.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.